Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
McKesson
Medtronic
Merck

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Muromonab

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug Muromonab?

Muromonab is an investigational drug.

There have been 10 clinical trials for Muromonab. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Preleukemia, Leukemia, and Myelodysplastic Syndromes. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Fred Hutchinson Cancer Research Center.

There are sixty-two US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Muromonab
TitleSponsorPhase
Trial of Adoptive Immunotherapy With TRACT to Prevent Rejection in Living Donor Kidney Transplant RecipientsNorthwestern UniversityPhase 1
Oral OKT3 for the Treatment of Active Ulcerative ColitisBrigham and Women's HospitalPhase 1/Phase 2
Safety and Efficacy of Basiliximab, Delayed Dose Tacrolimus Plus ECMPA Following Liver TransplantationNovartisPhase 4

See all Muromonab clinical trials

Clinical Trial Summary for Muromonab

Top disease conditions for Muromonab
Top clinical trial sponsors for Muromonab

See all Muromonab clinical trials

US Patents for Muromonab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Muromonab   Start Trial Agent for the treatment and or prophylaxis of an autoimmune disease and for the formation of regulatory T cells AiCuris GmbH & Co. KG (Wuppertal, DE)   Start Trial
Muromonab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Muromonab   Start Trial Cyclotides as immunosuppressive agents Universitatsklinikum Freiburg (Freiburg, DE) Medizinische Universitat Wien (Vienna, AT)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Harvard Business School
Moodys
Merck
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.